SNC-80

Research use only, not for human use.

A highly selective, non-peptide agonist of the δ-opioid receptor (δ-OR) with IC50/Ki of 2.73/0.18 nM; displays >2,000-fold selectivity over the μ-opioid receptor.

A highly selective, non-peptide agonist of the δ-opioid receptor (δ-OR) with IC50/Ki of 2.73/0.18 nM; displays >2,000-fold selectivity over the μ-opioid receptor; selectively activates μ-δ heteromers to produce maximal antinociception.Pain Discontinued.

SNC80 selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 exhibits substantially greater activity in cells coexpressing μ- and δ-opioid receptors than in cells either singly expressing δ-opioid receptors or coexpressing δ- and κ-opioid receptors.

SNC80 (10 mg/kg; intraperitoneal injection; once; C57BL6/J mice) treatment significantly attenuated this allodynia caused by overuse of Sumatriptan. Animal Model:Male and female C57BL6/J mice (20-30g) injected with Sumatriptan Dosage:10 mg/kg Administration:Intraperitoneal injection; once Result:Significantly attenuated allodynia.

NIH-10815

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

Neurological Disease

Pain

156727-74-1

449.6

C28H39N3O2

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (74.13 mM)

O=C(N(CC)CC)C1=CC=C([C@@H](N2[C@@H](C)CN(CC=C)[C@H](C)C2)C3=CC=CC(OC)=C3)C=C1

4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethyl-benzamide

(-20℃)

With Ice Pack

≥ 2 years